Biotechnology | COVID-19 | Diagnostics | NIH
NIH-funded screening study builds case for frequent COVID-19 antigen testing
On Jun. 30, 2021, the National Institutes of Health announced a highly anticipated study that compared rapid antigen…
Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…
Biden Administration invested $3 billion from American Rescue Plan as part of COVID-19 antiviral development strategy
On Jun. 17, 2021, the Biden Administration is investing more than $3 billion to accelerate the discovery, development…
KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
On Jun. 16, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…
NIH researchers identified potential new antiviral drug for COVID-19
On Jun. 3, 2021, the National Institutes of Health announced that the experimental drug TEMPOL may be a…
HHS launched first venture capital partnership to develop transformative technologies to combat future pandemics
On Jun. 1, 2021, the U.S. Department of Health and Human Services (HHS) unveiled a new type of…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, the National Institutes of Health (NIH) announced the first-in-human, Phase 1 trial assessing the…
Biotechnology | Diagnostics | FDA | Infectious Disease | NIH | Therapeutics
NIAID scientists found that Salmonella use intestinal epithelial cells to colonize the gut
On May 26, 2021, National Institutes of Health (NIH) scientists reported that the immune system’s attempt to eliminate…
Trevena announced TRV027 selected by NIH-funded ACTIV initiative for COVID-19 trial
On May 6, 2021, Trevena announced that TRV027, the Companyﾒs novel AT1 receptor selective agonist, had been selected…
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in additional grants…
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Life Science History | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
COVID-19 vaccine responses studied in people with immune deficits
On Apr. 23, 2021, the NIH announced that a study assessing how people with immune system deficiencies or…
Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients began
On Apr. 22, 2021, the NIH announced that a phase 3 trial to test the safety and efficacy…
Large NIH clinical trial tested polyclonal antibody therapeutic for COVID-19
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…
Large clinical trial launched to study repurposed drugs to treat COVID-19 symptoms
On Apr. 19, 2021, the NIH announced that it was funding a large, randomized, placebo-controlled Phase 3 clinical…
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
Most differences in DNA binding compounds found at birth in children conceived by IVF not seen in early childhood
On Apr. 14, 2021, National Institutes of Health researchers reported that a study which compared to newborns conceived…
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
Biotechnology | COVID-19 | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
NIH clinical trial evaluating Moderna COVID-19 variant vaccine began
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
Scientists found evidence that novel coronavirus infects the mouth’s cells
On Mar. 25, 2021, an international team of scientists announced they had found evidence that SARS-CoV-2 infects cells…
Investigational AstraZeneca vaccine prevented COVID-19
On Mar. 22, 2021, the NIH announced that results from a large clinical trial in the U.S. and…
Rigel announced completion of patient enrollment for phase 2 trial of fostamatinib in hospitalized COVID-19 patients
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
NIH scientists used human cerebral organoid to test drug for deadly brain disease
On Mar. 9, 2021, the NIH announced that approximately two years after establishing a human cerebral organoid system…
NIH launched last phase 3 clinical trial to evaluate safety and effectiveness of blood thinners in adults with COVID-19
On Mar. 8, 2021, the NIH announced that it had launched the last of three phase 3 clinical…
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
Biotechnology | Disease | Neurology | NIH | Therapeutics
NIH invested in next iteration of public-private partnership to advance precision medicine for Alzheimer’s disease
On Mar. 2, 2021, the NIH announced it had launched the next version of the Accelerating Medicines Partnership…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…